Background {#Sec1}
==========

Histoplasmosis is caused by a dimorphic saprophytic fungus, *Histoplasma capsulatum* which presents two variants: *Histoplasma capsulatum var. capsulatum* (*Hcc*) and *Histoplasma capsulatum var. duboisii* (*Hcd*)*. Hcc* is commonly found in soil contaminated with bird or bat droppings. Primary infection occurs through inhalation of spores \[[@CR1]\]*.*

*Hcc* can take different clinical forms including Disseminated Histoplasmosis (DH) in immunocompromised individuals, such as patients with Acquired Immune Deficiency Syndrome (AIDS). DH is associated with AIDS in 70% to 90% of cases in endemic countries such as South American countries; however, it remains extremely rare in European countries. DH can involve various organs and naso-oral histoplasmosis is an uncommon manifestation of DH \[[@CR2], [@CR3]\].

This article reports the first case of nasal-oral histoplasmosis with naso-maxillar osteolysis in a patient infected by Human Immunodeficiency Virus (HIV) at AIDS stage, in a non-endemic country. Naso-maxillar osteolysis can be observed in tumors, infections, granulomatosis, vasculitis or drug exposure.

Our aim is to describe the clinical presentation, the diagnoses issues and the etiologic and functional treatments of naso-oral histoplasmosis.

Case presentation {#Sec2}
=================

We report the case of a 53 year-old woman, originally from Haiti, living in France since 1989. She was hospitalized in the infectious diseases department of Bichat Claude Bernard University Hospital in Paris in March 2016 for alteration of general condition, fever and nasal deformity evolving for at least 6 months.

Her medical history is characterized by an HIV infection diagnosed in 2006, which was classified at AIDS stage in 2008 due to cytomegalovirus infection. At the same time, she suffered from pulmonary histoplasmosis that was treated with itraconazole. CD4 cell count nadir amounted to 7/mm^3^ in 2008. A first line of Highly Active Antiretroviral Therapy (HAART) was started 3 weeks after those diagnoses consisting in Efavirenz (EFV), Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC). After 1,5 months the patient decided to interrupt this treatment, a second line of HAART was initiated 6 months later with nevirapine and TDF/FTC. She only took secondary prophylaxis with itraconazole for 6 months and then stopped being compliant with any treatment and was lost to follow-up over 7 years. No history of recent travel to endemic areas or contact with neither birds nor bats was reported. She never smoked, did not have excessive alcohol consumption and did not inhale any nasal drugs.

At hospital admission, physical examination revealed a nasal tip collapse, a disappearance of the nasal septum and a large perforation of the hard palate, resulting in naso-oral communication. Facial skin, alar and triangular cartilages were undamaged. However, maxillary teeth \[[@CR4], [@CR5]\] were loose, and teeth 11, 21 and 22 fell spontaneously. Mucosa of the nasal cavity was ulcerated with crusts and partially necrotic (Fig. [1](#Fig1){ref-type="fig"}). The sinus CT-scan and the magnetic resonance imaging performed showed: a complete loss of the nasal septum, a maxillar osteolysis, a communication between oral and nasal cavities and bilateral maxillary sinus opacities (Fig. [2](#Fig2){ref-type="fig"}). The chest X-ray showed an interstitial pneumonia. She did not manifest dyspnea, cough, cutaneous eruption, neurologic deficit, visceromegaly or lymphadenopathy. HIV viral load was 56,943 copies/ml and CD4 cell count was 9/mm^3^ (2%). In blood: Treponema Pallidum Hemagglutination Assay and Veneral Disease Research Laboratory, *Cryptococcus* antigen, *Toxoplasma* polymerase chain reaction (PCR), *Leishmania* PCR, galactomannan antigen, blood and mycological (×4) cultures were all negative. β-D-Glucane was positive at 338 pg/ml. Blood *Hcc* PCR was positive. In bronchoalveolar fluid: cultures, *Cryptococcus* antigen were negative, *Pneumocystis jirovecii* PCR level was barely positive (18,000 copies/mL), After 3 months, *Mycobacterium tuberculosis* sputum cultures were negative.Fig. 1Clinical presentation of the case. **a**: Three-quarter picture of the face; **b**: Profile picture of the face; **c**: Face picture of the face showing lack of teeth 11, 21 and 22 which fall spontaneously; **d**: Bottom view of the face: nasal tip collapse, hard palate lysis and remaining nasal septum through the hole Fig. 2Imaging exploration. **a**: Sinus CT-scan showing bony nasal septum lysis and bilateral maxillary sinus opacities; **b** and **c**: Gadolinium-enhanced T1 weighted MRI (**b**: axial section; **c**: frontal section) showing bony nasal septum lysis and maxillar lysis without enhanced tumor mass

Surgical biopsies of oral, nasal and maxillary mucosa were performed and analyzed. Microscopic examination revealed fungal yeasts (Fig. [3](#Fig3){ref-type="fig"}), mycological cultures identified the presence of *Hcc* then confirmed by PCR.Fig. 3Histological analysis of naso-maxillar biopsy. **a** and **c**: Grocott staining; **b**: Gram Wegert staining; **d**: PAS staining

Those tests enabled a final diagnosis of DH with naso-oral involvement in an AIDS-stage patient.

The patient received 200 mg per day of intravenous Amphotericin B (AmphoB) liposomal for 1 month. In the follow-up, we observed: negativation of blood histoplasmosis PCR in 10 days and clinical stabilization of naso-maxillary osteolysis with normalization of mucosa. Treatment was switched to 400 mg of oral itraconazole per day for a minimum of 1 year, in accordance with international guidelines \[[@CR6]\].

HAART by ritonavir-boosted darunavir and TDF/FTC was reintroduced after 3 weeks of positive response to DH treatment. After 6 months, HIV viral load was undetectable and CD4 cell count at 40/mm^3^. At 9 months, biological results were stable and she had gained 17 k. Strategy of directly observed therapy permitted full compliance and the patient didn't report any side effect with any treatment. Blood levels of itraconazole and HAART were both in the standards.

Ulceration and inflammation of the mucus decreased, enabling a palatal prosthesis to be implemented. A reconstructive surgery will be proposed to the patient upon completion of antifungal therapy and stabilization of HIV infection.

Discussion {#Sec3}
==========

In immunocompromised individuals such as AIDS patients, especially when CD4 cell count is under 150/mm^3^, *Hcc* can produce a DH involving various organs, such as: liver, spleen, bone marrow, lymphnodes, gastrointestinal tract and central nervous system \[[@CR2], [@CR7]\]. Oral histoplasmosis is a rare lesion in DH and is hardly documented even in endemic regions. Palate, gingiva and tongue are the most frequently locations \[[@CR3], [@CR8]\]. Naso-maxillar histoplasmosis is extremely rare; we report the first case in a non-endemic country. It has previously been described that the lower CD4 T cell count is, the higher the probability of nasal and mucous lesion as manifestation of DH \[[@CR7], [@CR9], [@CR10]\]. Our patient's very low CD4 T cell counts supports this hypothesis.

Other etiologies of naso-maxillar osteolysis have to be discussed and ruled out: i) non-infectious etiologies (malignant tumors, Wegener's granulomatosis, sarcoidosis and consequences of drug exposure) and ii) other infectious etiologies (tuberculosis, leprosy, leishmaniosis, paracoccidioidomycosis and mucormycosis). The most frequent infectious cause of nasal lesion in AIDS patients is leishmaniosis.

The issue is that histoplasmosis can be confused with leishmaniosis for the following reasons: first of all *Histoplasma* yeasts could be interpreted as *Leishmania* amastigotes in direct examination; second, leishmaniosis frequently affects nasal mucosa \[[@CR11], [@CR12]\].

Because of its severity, mucormycosis must be explored and ruled out in this context, since very similar cases of maxillary osteolysis have been reported \[[@CR13]\].

Chronic nasal ulcerations and nasal septum perforation can be symptoms of vasculitis, especially granulomatosis with polyangiitis (GPA) also known as Wegener's granulomatosis. Unfortunately, the histological results show the classical triad of granulomatous inflammation, necrosis and vasculitis in up to 16% of cases of GPA. Diagnosis of GPA is based on a combination of clinical symptoms, histology and positive c-ANCA serology \[[@CR14]\]. One case of naso-septal perforation related to Takayashu's arteritis is reported \[[@CR4]\]. In Behçet disease, patients with nasal mucosa involvement do not have more nasal manifestations than those without \[[@CR15]\]. However no case of maxillary osteolysis caused by vasculitis has been reported in the literature so far.

An increasing cause of midface destructive lesions is cocaine exposure. Ischemia, mucociliar clearance modification, bacterial infection and lesions due to intranasal consumption lead to septal and hard palate perforation \[[@CR16], [@CR17]\]. In this context, a rise of c-ANCA may be possible, and may lead to a misdiagnosis with GPA. Nevertheless, necrosis and inflammation without vasculitis would be observed at histology examination \[[@CR18]\].

At last, maxillary osteolysis can be observed in malignant tumors like mucoepidermoid carninoma, squamous-cell carcinoma and lymphoma \[[@CR19], [@CR20]\]. Extranodal NK/T-cell lymphoma associated with Epstein-Barr virus infection has to be highlighted because of its severity and the difficulties to diagnose it. It can lead to a misdiagnosis such as GPA \[[@CR21], [@CR22]\].

In literature only 18 cases of nasal mucosa involvement due to *Hcc* have been reported (Table [1](#Tab1){ref-type="table"}). Three of them died because of delay in introducing treatment or non-adherence to treatment. Treatment was either AmphoB or itraconazole. Among patients, 12 had HIV related immunodeficiency, when it was reported, CD4 cell counts was always \<150/mm^3^.Table 1Clinical characteristics of nasal and oral histoplasmosis in 18 patientsN°/RefSexAge (years)Risk FactorCD4 (/mm3)Clinical PresentationDiagnosisLocationTreatmentFollow up (M: months)Country1 \[[@CR31]\]M32HIV infection60PainHistologyNasal septum perforationAmphotericin B then itraconazole6 M, ImprovementColombia2 \[[@CR31]\]F37HIV infection133Nasal itch, epistaxis, nasal dischargeHistologyNasal septum perforationItraconazole2 M, ImprovementColombia3 \[[@CR32]\]M59HCV infectionNose wound with crustNot availableNasal ulceration covered by crustsItraconazole1 M, ImprovementBrazil4 \[[@CR33]\]M27HIV infection20Fatigue, fever, skin lesions, dyspneaHistologyDisseminated (nasal ulceration and cutaneous)Amphotericin B then itraconazoleImprovementArgentina5 \[[@CR34]\]M37HIV infectionNot availableFever, dysphagia, inflammatory and hemorrhagic nasal processHistologyDestruction of nasal septumNo treatmentDeathBrazil6 \[[@CR35]\]M30NoneNasal swellingHistologyNasal crustsItraconazoleLost follow-upIndia7 \[[@CR23]\]F79FarmerFatigue, nasal obstructionHistologyNasal ulceration and crustsItraconazoleLost follow-upUSA (Ohio)8 \[[@CR36]\]M37Renal transplant, HBV/HCV coinfectionNose septal destructionNot availableUlceration in mouth and noseAmphotericin B then itraconazole1 M, ImprovementBrazil9 \[[@CR37]\]F32HIV infection69Fatigue, fever, nasal pain, nasal pyramid collapseHistologyDestruction of the cartilaginous septum, columella and left nasal wing, and ulcerationsAmphotericin B12 M, ImprovementBrazil10 \[[@CR38]\]M39HIV infection20Nasal congestion, post nasal rhinorrhea, coughHistologySinusitis, Skin rash, pulmonary involvementItraconazoleImprovementUSA (La)11 \[[@CR39]\]F49HIV infectionNot availableNasal obstructionHistology and cultureLesion on the nasal vestibule and septumNot availableDeathBrazil12 \[[@CR39]\]F23HIV infectionNot availableNot availableHistologyCrustsAmphotericin B then itraconazoleImprovementBrazil13 \[[@CR40]\]M43HIV infection, farmer15Nasal regurgitationHistologyComplete destruction of the nasal architecture, palatal perforationItraconazoleImprovementBrazil14 \[[@CR41]\]M39HIV infection120Nasal obstruction, post nasal rhinorrhea, headache, epistaxisHistologyPapular and nodular rash, polypoid and inflammatory nasal mucosa in the right nasal fossa, bulging posterior wall of the nasopharynxAmphotericin BImprovementMorocco15 \[[@CR42]\]M30Adrenal insufficiencyVisual acuity impairment, nasal, septum and soft palate lesionsHistologyEndophtalmitis, nasal, septum and soft palate lesionsAmphotericin B (intraocular injection), itraconazole12 W, ImprovementArgentina16 \[[@CR43]\]NANAHIV infectionNot availableNot availableNot availableMouth, gingivae, hard palate, right maxillary sinus, right nasal cavityNot availableNot availableSouth Africa17 \[[@CR44]\]M76Chronic lymphocytic leukemiaEpistaxis and facial pain, facial erythema, swelling, and feverHistology and cultureEthmoïdal, sphenoidal and maxillary sinusitisAmphotericin B then itraconazoleImprovementBrazil18 \[[@CR45]\]M36HIV infection, drug abuseNot availableFever, orodyniaHistologyUlceration on the nasal bridge, necrotizing gingivitis and granulomatous oral lesionKetoconazole4 M, DeathBrazil

Rizzi and *al*. reported a case of nasal histoplasmosis in an immunocompetent 79-year-old woman with nasal obstruction. Based on the histopathological examination, it was misdiagnosed with sarcoidosis and aggravation was observed on corticosteroids \[[@CR23]\].

Generally speaking, diagnosis of histoplasmosis can be difficult because of its low frequency, its non-specific clinical presentation and some histological similarities with others causes of nasal damage \[[@CR5], [@CR11]\].

A review of literature reported only 72 patients with AIDS having presented histoplasmosis in Europe between 1984 and 2004 \[[@CR24]\]. The diagnosis of histoplasmosis is based on mycological examination, antigen detection or detection of *Histoplasma* DNA by PCR. The limits are: the unlikelihood to see yeast with GIEMSA staining, the duration of the culture (up to 4 weeks) and its lack of sensitivity \[[@CR25]\].

Antigen detection is quick (within 24 h) and allows monitoring response to treatment \[[@CR26]\]. Unfortunately, this test is not available in non-endemic countries. Besides, false negatives results can occur especially in immunocompromised patients, as well as false positives results because of cross-reaction with other fungal infections \[[@CR27]\]. In European countries, galactomannan antigen is usually used as a surrogate marker of histoplasmosis, especially on HIV patients. The sensitivity of this test is proportional to fungal load \[[@CR28]\]. The negative result in our case study may be explained by the fact that it was conducted after treatment initiation.

Thanks to development of genetic diagnostic tools, histoplasmosis DNA can be detected by PCR either on blood sample or on tissue specimens. Its very good sensitivity, its 100% of specificity, and the rapidity to obtain the results make it the most reliable test as of today \[[@CR29], [@CR30]\]. Thus, if available, PCR must be performed on blood and tissue samples as soon as the diagnosis of histoplasmosis is suggested.

Conclusion {#Sec4}
==========

Nasal histoplasmosis should be suspected for patients coming from endemic region, with deep immunosuppression (especially in AIDS patients).

Our patient is the first case of nasal architecture destruction by *Hcc* reported to date in a non-endemic region. After 1 year of treatment, she has had a really encouraging clinical course with good compliance illustrated by: controlled HIV infection, controlled DH and significant weight gain.

Given the very wide range of etiologies, the non-specific symptoms and the difficulty of histological analysis, a reliable diagnosis requires a thorough knowledge of maxillary osteolysis causes and an efficient cooperation and communication between surgeon, infectious disease clinician, mycologist and pathologist.
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